Why the study?
Does withholding versus continuing ACEIs or ARBs before noncardiac surgery reduce the 30-day composite outcome of all-cause death, myocardial injury, and stroke?
Population
Patients on angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers undergoing…
Comparison
Withholding angiotensin-converting enzyme… vs Continuing angiotensin-converting enzyme…
Design
Cohort
Follow-up
30 days
Authors
Loading...
Withholding ACEIs/ARBs may lower perioperative risk; leaves open need for RCTs before practice change.
Does withholding versus continuing ACEIs or ARBs before noncardiac surgery reduce the 30-day composite outcome of all-cause death, myocardial injury, and stroke?
Roshanov et al. (2017) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: